BioVista Ventures develops and prepares therapeutic assets originated from Brazilian science for international biotechnology development — identifying promising research, de-risking it, and connecting it to global pathways.
Brazilian science produces strong therapeutic hypotheses, but many never reach international development — not for lack of quality, but for lack of structured de-risking and preparation. BioVista Ventures was created to close that gap: to identify, de-risk and prepare therapeutic science so its value can be unlocked globally.
Finding therapeutic science with genuine potential — research originated in Brazilian laboratories and institutions that addresses real unmet needs.
Doing the disciplined early work: strengthening data packages, clarifying development paths and reducing the scientific and translational uncertainty around each asset.
Preparing assets for global biotechnology development — connecting de-risked science to international partners, capital and development infrastructure.
As founder, Ravi Kaiut brings his combined background in neuroscience research and organization-building to BioVista — evaluating science, shaping development strategy and connecting Brazilian research to the global biotechnology ecosystem. Details of specific assets, partners and transactions are confidential and are not published on this personal site.
Visit BioVista Ventures — biovista.ventures